Strides Arcolab in JV with US-based Accu-Break

Strides Arcolab has signed a definitive agreement with Accu-Break Pharma
to set up a world-wide joint venture company (JVC) to develop a generic product line using patent pending Accu-Break technologies.

According to an official release issued to the BSE today, the 50:50 JV, to be called Accu-Strides, will outsource an exclusive product pipeline of generic and ANDA products in finished dosage forms from Strides Arcolab.

Accu-Strides will outsource pharmaceuticals sales, marketing and distribution capabilities for north American markets from Accu-Break while Strides will provide sales, marketing and distribution capabilities for the rest of the world.

The product dossiers developed for Accu-Strides by Strides-Arcolab will be owned exclusively by Accu-Strides.

"The Accu-Break and Strides JVC is a true reflection of the "Strides Value" partnership model. Using our niche manufacturing and product development skill sets, Strides will ramp-up the product pipeline to leverage various Accu-Break technologies to create a worldwide specialty generic pharmaceutical company. We will work towards creating critical mass for the JVC and significant value to all stakeholders," Arun Kumar, vice-chairman and group CEO of Strides-Arcolab, said.